fluorouracil has been researched along with Kahler Disease in 29 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Forty-four patients with progressive symptomatic multiple myeloma were treated with a protocol combining cyclophosphamide (10 mg/kg weekly), procarbazine (2 mg/kg daily), prednisolone (20 mg daily), and either BCNU (1 mg/kg weekly) (BCPP protocol) or MCNU (0." | 7.67 | [Combination chemotherapy of multiple myeloma--BCNU.cyclophosphamide.procarbazine.prednisolone and MCNU.cyclophosphamide.procarbazine.prednisolone therapy]. ( Ito, T; Komatsu, M; Saito, Y; Takahashi, H; Uzuka, Y, 1989) |
| "Despite major advances, multiple myeloma (MM) remains an incurable malignancy." | 5.33 | Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells. ( Alsina, M; Beam, C; Beaupre, DM; Dalton, W; Gerbino, E; Hamilton, AD; Kerr, WG; Lichtenheld, MG; Mackley, PA; Muro-Cacho, C; Sebti, SM; Zhu, K, 2005) |
| "Perifosine is a novel targeted oral Akt inhibitor currently in Phase III clinical development for treatment of colorectal cancer (CRC, in combination with capecitabine) and multiple myeloma (MM, in combination with bortezomib and dexamethasone)." | 3.78 | Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. ( Anderson, KC; Eng, C; Hideshima, T; Kolesar, J; Richardson, PG, 2012) |
| "Forty-four patients with progressive symptomatic multiple myeloma were treated with a protocol combining cyclophosphamide (10 mg/kg weekly), procarbazine (2 mg/kg daily), prednisolone (20 mg daily), and either BCNU (1 mg/kg weekly) (BCPP protocol) or MCNU (0." | 3.67 | [Combination chemotherapy of multiple myeloma--BCNU.cyclophosphamide.procarbazine.prednisolone and MCNU.cyclophosphamide.procarbazine.prednisolone therapy]. ( Ito, T; Komatsu, M; Saito, Y; Takahashi, H; Uzuka, Y, 1989) |
| "Eleven patients with multiple myeloma or breast cancer had cyclophosphamide and filgrastim-mobilized PB cells CD34-enriched and transduced with a retroviral marking vector containing the neomycin resistance gene, and CD34-enriched BM cells transduced with a second marking vector also containing a neomycin resistance gene." | 2.68 | Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. ( Berenson, R; Brown, S; Carter, C; Cottler-Fox, M; Doren, S; Dunbar, CE; Greenblatt, J; Moen, RC; O'Shaughnessy, JA; Stewart, FM, 1995) |
| "Multiple myeloma is a plasma cell malignancy that thrives in the bone marrow (BM), with frequent progression to new local and distant bone sites." | 1.56 | Runx2 Deficiency in Osteoblasts Promotes Myeloma Progression by Altering the Bone Microenvironment at New Bone Sites. ( Gowda, PS; Javed, A; Li, J; Lu, Y; Ponnazhagan, S; Trotter, TN; Xu, X; Yang, Y; Zhang, C, 2020) |
| "The relevant literature regarding treatment of liver cirrhosis complicated with HCC and synchronous colon Ca reveals poor and controversial outcomes." | 1.38 | How can we treat a patient with liver cirrhosis (hepatitis C virus), hepatocellular carcinoma, and synchronous colon cancer? ( Antoniou, E; Dimitroulis, D; Kostakis, A; Labadariou, A; Mantas, D; Nikitakis, N; Paraskeva, P; Smyrnis, A; Tsavaris, N; Vernicos, P, 2012) |
| "5-Fluorouracil (5FU) is a nucleoside analog and is used as an anti-tumor agent in patients whose plasma dCyd concentrations are increased." | 1.36 | 2'-Deoxycytidine decreases the anti-tumor effects of 5-fluorouracil on mouse myeloma cells. ( Iwazaki, A; Yoshioka, M, 2010) |
| "Despite major advances, multiple myeloma (MM) remains an incurable malignancy." | 1.33 | Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells. ( Alsina, M; Beam, C; Beaupre, DM; Dalton, W; Gerbino, E; Hamilton, AD; Kerr, WG; Lichtenheld, MG; Mackley, PA; Muro-Cacho, C; Sebti, SM; Zhu, K, 2005) |
| "Acute hyperammonemia is a medical emergency for which immediate steps must be taken to minimize permanent brain damage." | 1.32 | Unusual causes of hyperammonemia in the ED. ( Chen, WJ; Shih, FF; Weng, TI, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 18 (62.07) | 18.7374 |
| 1990's | 2 (6.90) | 18.2507 |
| 2000's | 4 (13.79) | 29.6817 |
| 2010's | 4 (13.79) | 24.3611 |
| 2020's | 1 (3.45) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, X | 1 |
| Zhang, C | 1 |
| Trotter, TN | 1 |
| Gowda, PS | 1 |
| Lu, Y | 1 |
| Ponnazhagan, S | 1 |
| Javed, A | 1 |
| Li, J | 1 |
| Yang, Y | 1 |
| Iwazaki, A | 2 |
| Yoshioka, M | 2 |
| Imai, K | 1 |
| Nakanishi, K | 1 |
| Richardson, PG | 1 |
| Eng, C | 1 |
| Kolesar, J | 1 |
| Hideshima, T | 1 |
| Anderson, KC | 1 |
| Antoniou, E | 1 |
| Mantas, D | 1 |
| Paraskeva, P | 1 |
| Dimitroulis, D | 1 |
| Smyrnis, A | 1 |
| Nikitakis, N | 1 |
| Labadariou, A | 1 |
| Tsavaris, N | 1 |
| Vernicos, P | 1 |
| Kostakis, A | 1 |
| VOLK, H | 1 |
| ROBERTS, TW | 1 |
| COOPER, P | 1 |
| GOLDRING, IP | 1 |
| WOODRUFF, MW | 1 |
| MURPHY, WT | 1 |
| HODSON, JM | 1 |
| FALKSON, G | 1 |
| SNYMAN, HJ | 1 |
| Weng, TI | 1 |
| Shih, FF | 1 |
| Chen, WJ | 1 |
| Zhu, K | 1 |
| Gerbino, E | 1 |
| Beaupre, DM | 1 |
| Mackley, PA | 1 |
| Muro-Cacho, C | 1 |
| Beam, C | 1 |
| Hamilton, AD | 1 |
| Lichtenheld, MG | 1 |
| Kerr, WG | 1 |
| Dalton, W | 1 |
| Alsina, M | 1 |
| Sebti, SM | 1 |
| Namba, M | 1 |
| Miyoshi, T | 1 |
| Kanamori, T | 1 |
| Nobuhara, M | 1 |
| Kimoto, T | 1 |
| Ogawa, S | 1 |
| Dunbar, CE | 2 |
| Cottler-Fox, M | 1 |
| O'Shaughnessy, JA | 1 |
| Doren, S | 1 |
| Carter, C | 1 |
| Berenson, R | 1 |
| Brown, S | 1 |
| Moen, RC | 1 |
| Greenblatt, J | 1 |
| Stewart, FM | 1 |
| Nienhuis, AW | 1 |
| Cao, S | 1 |
| Baccanari, DP | 1 |
| Rustum, YM | 1 |
| Davis, ST | 1 |
| Tansik, RL | 1 |
| Porter, DJ | 1 |
| Spector, T | 1 |
| de Boer, F | 1 |
| Dräger, AM | 1 |
| Van Haperen, MJ | 1 |
| van der Wall, E | 1 |
| Kessler, F | 1 |
| Huijgens, PC | 1 |
| Pinedo, HM | 1 |
| Schuurhuis, GJ | 1 |
| Bergsagel, DE | 3 |
| Lowenthal, RM | 1 |
| Jestrimski, KW | 1 |
| Kamiya, O | 1 |
| Hoshino, A | 1 |
| Ohara, K | 1 |
| Nagata, K | 1 |
| Ono, Y | 1 |
| Saito, M | 1 |
| Itou, T | 1 |
| Yamamoto, K | 1 |
| Uzuka, Y | 1 |
| Saito, Y | 1 |
| Takahashi, H | 1 |
| Komatsu, M | 1 |
| Ito, T | 1 |
| Wilmanns, W | 1 |
| Binsack, T | 1 |
| Sauer, H | 1 |
| Rieche, K | 1 |
| Arndt, A | 1 |
| Armstrong, JG | 1 |
| Frei, E | 1 |
| Schabel, FM | 1 |
| Goldin, A | 1 |
| Berenbaum, MC | 1 |
| Ogawa, M | 1 |
| McCulloch, EA | 1 |
| Teller, MN | 1 |
| Bowie, M | 1 |
| Mountain, IM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Trial of Autologous Transplantation With Filgrastim Versus Stem Cell Factor/Filgrastim-Primed CD34-Enriched Peripheral Blood Cells for Multiple Myeloma[NCT00001750] | Phase 2 | 32 participants | Interventional | 1998-09-30 | Completed | ||
| Follow-Up Study of Breast Cancer and Multiple Myeloma Subjects Previously Enrolled in Retroviral Gene Transfer Studies[NCT00427726] | 12 participants (Actual) | Observational | 2003-03-06 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for fluorouracil and Kahler Disease
| Article | Year |
|---|---|
The treatment of plasma cell myeloma.
Topics: Animals; Carmustine; Cytarabine; Doxorubicin; Drug Evaluation, Preclinical; Fluorouracil; Humans; Me | 1976 |
Corticosteroid drugs: their role in oncological practice.
Topics: Adrenal Cortex Hormones; Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Breast | 1986 |
An assessment of massive-dose chemotherapy of malignant disease.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Cell Division; Cyclo | 1971 |
1 trial available for fluorouracil and Kahler Disease
| Article | Year |
|---|---|
Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation.
Topics: Antigens, CD; Antigens, CD34; Bone Marrow Transplantation; Breast Neoplasms; Cyclophosphamide; Femal | 1995 |
Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation.
Topics: Antigens, CD; Antigens, CD34; Bone Marrow Transplantation; Breast Neoplasms; Cyclophosphamide; Femal | 1995 |
Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation.
Topics: Antigens, CD; Antigens, CD34; Bone Marrow Transplantation; Breast Neoplasms; Cyclophosphamide; Femal | 1995 |
Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation.
Topics: Antigens, CD; Antigens, CD34; Bone Marrow Transplantation; Breast Neoplasms; Cyclophosphamide; Femal | 1995 |
25 other studies available for fluorouracil and Kahler Disease
| Article | Year |
|---|---|
Runx2 Deficiency in Osteoblasts Promotes Myeloma Progression by Altering the Bone Microenvironment at New Bone Sites.
Topics: Animals; Bone and Bones; Bone Marrow; Bone Neoplasms; Cell Line, Tumor; Core Binding Factor Alpha 1 | 2020 |
2'-Deoxycytidine decreases the anti-tumor effects of 5-fluorouracil on mouse myeloma cells.
Topics: Animals; Antineoplastic Agents; Biomarkers; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Adm | 2010 |
Intravenously administered 2'-deoxycytidine suppresses mouse myeloma tumor growth.
Topics: Animals; Antineoplastic Agents; Deoxycytidine; Fluorouracil; Injections, Intravenous; Kidney; Liver; | 2012 |
Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Ca | 2012 |
How can we treat a patient with liver cirrhosis (hepatitis C virus), hepatocellular carcinoma, and synchronous colon cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Hepatocellular; Chemotherapy, Adj | 2012 |
The effect of 5-fluorouracil in human cancer in millipore diffusion chambers in vivo.
Topics: Fluorouracil; Humans; Multiple Myeloma; Plasma Cells | 1962 |
The use of combination 5-fluorouracil and supervoltage irradiation therapy in advanced carcinoma of the urinary bladder--a preliminary report.
Topics: Carcinoma; Cell- and Tissue-Based Therapy; Fluorouracil; Humans; Multiple Myeloma; Plasma Cells; Ura | 1962 |
EXPERIENCE WITH CHEMOTHERAPY OF CANCER AT THE UNIVERSITY OF PRETORIA.
Topics: Antineoplastic Agents; Aziridines; Breast Neoplasms; Cyclophosphamide; Dactinomycin; Fluorouracil; H | 1964 |
Unusual causes of hyperammonemia in the ED.
Topics: Adult; Aged; Anticonvulsants; Antimetabolites, Antineoplastic; Emergency Service, Hospital; Female; | 2004 |
Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr | 2005 |
Combined effects of 5-fluorouracil and interferon on proliferation of human neoplastic cells in culture.
Topics: Animals; Cell Line; Cell Transformation, Neoplastic; Drug Evaluation, Preclinical; Fibroblasts; Fluo | 1982 |
Multiple myeloma. New approaches to therapy.
Topics: Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Female; Fluorouracil; Gene | 1993 |
alpha-fluoro-beta-alanine: effects on the antitumor activity and toxicity of 5-fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; beta-Alanine; Colonic Neoplasms; Colorectal Neoplasms; Dru | 2000 |
The phenotypic profile of CD34-positive peripheral blood stem cells in different mobilization regimens.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; | 2000 |
[Combination chemotherapy of MCNU, melphalan, procarbazine, and prednisolone (MMPP) in multiple myeloma; disappearance of M-peak on serum electrophoretic pattern].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Doxorubicin; Drug Evalua | 1989 |
[Combination chemotherapy of multiple myeloma--BCNU.cyclophosphamide.procarbazine.prednisolone and MCNU.cyclophosphamide.procarbazine.prednisolone therapy].
Topics: Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 1989 |
[Cytostatic polychemotherapy in the aged].
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dac | 1985 |
[The effect of the clinically usual cytostatic therapy on cell-mediated immune reactions in tumor patients].
Topics: Breast Neoplasms; Bronchial Neoplasms; Cell Migration Inhibition; Cyclophosphamide; Drug Therapy, Co | 1973 |
Current problems in the use of the oncolytic drugs.
Topics: Antineoplastic Agents; Busulfan; Carcinoma, Squamous Cell; Child; Chlorambucil; Choriocarcinoma; Dac | 1968 |
Chemotherapy and immunity to cancer.
Topics: Allyl Compounds; Aniline Compounds; Animals; Antineoplastic Agents; Cyclophosphamide; Fluorouracil; | 1974 |
Comparative chemotherapy of AKR lymphoma and human hematological neoplasia.
Topics: Animals; Antineoplastic Agents; Biological Assay; Carmustine; Cyclohexanes; Cyclophosphamide; Cytara | 1974 |
In vivo determination of the fractional kill of human tumor cells by chemotherapeutic agents.
Topics: Antineoplastic Agents; Cell Survival; Cyclophosphamide; Fluorouracil; Humans; Melphalan; Multiple My | 1972 |
Chemotherapy of mouse myeloma: quantitative cell cultures predictive of response in vivo.
Topics: Animals; Antineoplastic Agents; Bone Marrow Cells; Cells, Cultured; Cyclophosphamide; Female; Fluoro | 1973 |
Influence of age of host on the chemotherapy of murine myeloma LCP-1.
Topics: Age Factors; Aging; Alkylating Agents; Animals; Antineoplastic Agents; Carmustine; Cyclophosphamide; | 1974 |
Cytotoxic agents in the treatment of malignant disease.
Topics: Antimetabolites; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Chlorambucil; Choriocarcinoma; | 1968 |